

Product datasheet for **KN213464LP**

BRCA2 Human Gene Knockout Kit (CRISPR)

Product data:

Product Type:	Knockout Kits (CRISPR)
Format:	2 gRNA vectors, 1 Luciferase-Puro donor, 1 scramble control
Donor DNA:	Luciferase-Puro
Symbol:	BRCA2
Locus ID:	675
Components:	KN213464G1 , BRCA2 gRNA vector 1 in pCas-Guide CRISPR vector (GE100002) KN213464G2 , BRCA2 gRNA vector 2 in pCas-Guide CRISPR vector (GE100002) KN213464LPD , donor DNA containing left and right homologous arms and Luciferase-Puro functional cassette. GE100003 , scramble sequence in pCas-Guide vector
Disclaimer:	These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
RefSeq:	<u>NM_000059</u>
UniProt ID:	<u>P51587</u>
Synonyms:	BRCC2; BROVCA2; FACD; FAD; FAD1; FANCD; FANCD1; GLM3; PNCA2; XRCC11
Summary:	Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]



[View online »](#)

Product images:

